Dapivirine Ring Evidence & Research
Studies show that the Dapivirine Ring reduces the risk of HIV infection and offers a discreet and long-acting alternative to daily oral PrEP.
Although access to daily oral PrEP is increasing around the world, a daily pill is not a suitable or desirable prevention method for everyone. Today, women account for more than half of all people living with HIV globally, and face persistently high rates of HIV infection. Furthermore, experience introducing oral PrEP in many countries has revealed that women face unique challenges when it comes to adhering to a daily pill regimen due to gender inequity and social norms.
The monthly Dapivirine Ring provides a solution to these challenges as a woman-initiated prevention option that can be used discreetly by women who are unable to negotiate condom use or unable to discreetly or consistently use daily oral PrEP. Efficacy data shows that the ring reduces HIV risk by 35 percent, with recent data from open label studies (DREAM and HOPE) showing greater reduction in HIV risk – 50 percent or more with consistent use of the ring. Modelling has shown that even a partially effective prevention option can have a major protective impact for women and their communities.
Click here to access the Ring 101 Slide Deck — these slides give an overview of the Dapivirine Ring, including basic information about how it’s used, clinical trial results, user experience, and upcoming studies and products.
Read below to find out more about: